Skip to content
ilts@ilts.org
Search:
Search
ILTS 2019
Toronto
ILTS 2019
ILTS 2019 - Logo
  • HOME
  • GENERAL INFORMATION
    • MESSAGE FROM ILTS
    • AWARDS
    • IMPRESSIONS OF ILTS 2019
    • CONGRESS VENUE
    • ABOUT TORONTO
    • CONGRESS CONTACTS
    • MEDIA & PRESS
    • PROMOTIONAL KIT
  • ABSTRACTS
    • ABSTRACTS
    • RISING STAR SYMPOSIUM
    • POSTERS
  • SCIENTIFIC PROGRAM
    • PROGRAM OUTLINE
    • SESSION FORMATS
    • SPECIAL EVENTS
    • SESSIONS PER MEDICAL SPECIALITY
  • REGISTRATION & HOTEL
    • REGISTRATION
    • ACCOMMODATION
    • SOCIAL EVENTS
  • EXHIBITORS & SUPPORTERS
    • WELCOME MESSAGE
    • INNOVATIONS IN BIOTECHNOLOGY
    • ACKNOWLEDGEMENT
    • EXHIBITOR LIST
    • AIFA
    • ETHICAL MEDTECH ASSESSMENT
  • ILTS
    • About ILTS
    • 2019 PROGRAM COMMITTEE
    • 2018 – 2019 ILTS COUNCIL
    • ILTS MEMBERSHIP
  • HOME
  • GENERAL INFORMATION
    • MESSAGE FROM ILTS
    • AWARDS
    • IMPRESSIONS OF ILTS 2019
    • CONGRESS VENUE
    • ABOUT TORONTO
    • CONGRESS CONTACTS
    • MEDIA & PRESS
    • PROMOTIONAL KIT
  • ABSTRACTS
    • ABSTRACTS
    • RISING STAR SYMPOSIUM
    • POSTERS
  • SCIENTIFIC PROGRAM
    • PROGRAM OUTLINE
    • SESSION FORMATS
    • SPECIAL EVENTS
    • SESSIONS PER MEDICAL SPECIALITY
  • REGISTRATION & HOTEL
    • REGISTRATION
    • ACCOMMODATION
    • SOCIAL EVENTS
  • EXHIBITORS & SUPPORTERS
    • WELCOME MESSAGE
    • INNOVATIONS IN BIOTECHNOLOGY
    • ACKNOWLEDGEMENT
    • EXHIBITOR LIST
    • AIFA
    • ETHICAL MEDTECH ASSESSMENT
  • ILTS
    • About ILTS
    • 2019 PROGRAM COMMITTEE
    • 2018 – 2019 ILTS COUNCIL
    • ILTS MEMBERSHIP

16730330-2

You are here:
  1. Home
  2. 16730330-2
Site Notice | Privacy Policy | My Cookie Preferences | Contact
Go to Top
Twitter
Facebook
LINKEDIN

  • Individualizing liver transplant immunosuppression
  • Individualizing liver transplant immunotolerance and Tregs
  • Biomarker for tolerance – who can have immunosuppression withdrawn?
  • Gene editing for graft function improvement
  • Regional immunoregulation on liver graft injury and disease recurrence
  • Impact of donor steatosis on short and long term outcome post LT – Western experience
  • Impact of donor steatosis on short and long term outcome post LT – Eastern experience
  • De-novo fatty liver post LT: Is this a new disease?
  • NASH and sarcopenia in listed LT patients
  • NASH recurrence post LT: targets treatment for prevention
  • Perioperative coagulation: Pro and Con
  • AKI prediction scores in DBD and DCD
  • Cirrhotic Cardiomyopathy
  • The brain and liver
  • When the lung contraindicates a liver transplant
  • Pre transplant evaluation and management of a patient with diffuse PVT on the waiting list: staging, medical management, anticoagulation
  • Converting untransplantable patients with chronic obliterative PVT and cavernoma to transplantability using trans-splenic portal vein recanalization TIPS
  • Outcomes of LT in a recipient with diffuse PVT: True survival benefit and implications for organ allocation
  • DEBATE: Surgical options in patients with diffuse (Grade 4 Yerdel) PVT: i) Liver transplant with inflow from vessels of all types and sizes is possible ii) Multi-Visceral Transplant is the best option iii) Discussion
  • DEBATE: Surgical options in patients with diffuse (Grade 4 Yerdel) PVT: i) Liver transplant with inflow from vessels of all types and sizes is possible ii) Multi-Visceral Transplant is the best option iii) Discussion
  • Expanding Indications for pediatric LT – How to identify the need?
  • Saving livers whilst saving lives in advanced hepatoblastoma: extended resection vs liver transplantation (Case Presenter + Discussant)
  • The agelessness of frailty in liver transplantation
  • Expanding the donor pool
  • The new development of pediatric LDLT in mainland China
  • NASH – potential perioperative problems
  • Histological findings in late paediatric post-transplant biopsies: what the pathologist sees that we don’t see
  • Subclinical chronic graft injury in very stable pediatric liver transplant recipients: What the clinician has to deal with?
  • The challenges with TOO LITTLE immunosuppression: Non-adherence – enough of the talk – what can we actually do about this?
  • The challenges with TOO MUCH immunosuppression: Extra-hepatic diseases in liver transplanted children and adolescents – cardiovascular, PTLD, renal
  • Transition from pediatric to adult care after pediatric liver transplantation: What do adult care teams need from the pediatric teams?
  • An evidence based review of TEG/ROTEM guided coagulation management
  • Treatment and prophylaxis of pre- and postoperative thromboses
  • Transplanting a DCD-liver: perioperative challenges
  • Extracorporeal liver support in ALF and ACLF
  • Transplant Center Performance is Adequately Reflected in 1yr Graft and Patient Survival a) Yes b) No
  • Transplant Center Performance is Adequately Reflected in 1yr Graft and Patient Survival a) Yes b) No
  • DCD should only go to “healthy” recipients:  a) Yes b) No
  • DCD should only go to “healthy” recipients:  a) Yes b) No
  • Simultaneous liver and kidney transplant vs. sequential kidney after liver transplant in decompensated CLD with AKI: Which is more feasible and safe? a) SLKT b) Sequential transplant
  • Beyond patient and graft survival: How do we know that we are any good?
  • ERAS for Liver Transplantation
  • Re-weight the value of liver transplantation – the recipient benefit
  • Re-weight the value of liver transplantation – the donor benefit
  • The role of multidisciplinary care
  • Smart matching: applying artificial neural networks in liver transplantation
  • Curative ex vivo hepatocyte – directed gene editing: how far away from reality?
  • Ex situ machine perfusion as a tool to recondition steatotic donor livers
  • Precision transplant pathology
  • Molecular scissors: Gene editing applied to liver transplantation – new approaches to modeling liver diseases
  • Organ allocation for patients with cancer
  • Response to LRT and other surrogates of tumor biology: importance for transplant outcomes in HCC
  • Time to think of liver transplantation for intrahepatic cholangiocarcinoma
  • Ex vivo liver resection and autotransplantation for end-stage hepatic alveolar echinococcosis
  • The new pipeline of drugs in transplant oncology
  • Solving an imbalanced liver transplantation problem: AI and efficient decision-support models for liver allocation
  • Pitfalls of current allocation systems in US
  • Pitfalls of current allocation systems in Europe
  • Current organ allocation system in mainland of China
  • Shifting allocation from living donation to deceased donation
  • Sepsis in the post-transplant patient
  • Acute but different – key management decisions in ACLF vs. ALF
  • Hepatopulmonary syndrome – path to successful transplantation
  • Frailty in ICU: implications for transplant candidacy
  • Surgical planning for living donor liver transplant using 4D flow MRI, computational fluid dynamics and in vitro experiments
  • Current State-of-the-Art MRI for comprehensive evaluation of otential living liver donors
  • 3-D visualized and VR technology in liver surgery
  • Liver histopathology: from normal to diseased conditions requiring liver transplantation
  • HCC diagnosis in pretransplant and explanation liver: what we shouldn’t miss
  • Pathology of hepatic vascular disorders and their relevance to liver transplantation